[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 139
6. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685109.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


7. De Raffele E, Mirarchi M, Vaccari S, Santini D, Calculli L, Pendino GM, Cola B: [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms]. Chir Ital; 2009 Sep-Dec;61(5-6):667-77
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Echo-guided spleen-preserving resection of the pancreas tail for pancreatic intraductal papillary mucinous neoplasms].
  • [Transliterated title] Resezione della coda del pancreas "spleen preserving" ecoguidata per neoplasia intraduttale mucinosa (IPMN) del pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are a distinct entity with malignant potential, which may recur after surgical excision.
  • We report our technique of intraoperative US-guided resection of non-invasive IPMNs located in the tail of the pancreas with spleen and splenic vessel preservation.
  • Following adequate exposure of the distal pancreas, a thorough ultrasonographic examination of the parenchyma is accomplished to define the features of the neoplasia, its relationship with the main pancreatic duct and splenic vessels and to mark the transection line with electrocautery.
  • Patient 2 was a 60-year-old male who underwent intraoperative US-guided resection of the pancreatic tail for an IPMN of the pancreatic tail measuring 30 mm with carcinoma in situ at histology, and was discharged 9 days after surgery.
  • Limited distal pancreatic resection with spleen and splenic vessel preservation is an adequate surgical technique for non-invasive IPMN of the tail of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreatic Neoplasms / ultrasonography. Spleen

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380276.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Zhang L, Sanderson SO, Lloyd RV, Smyrk TC: Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1191-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
  • Morphologic, clinical, and genetic evidence suggests that pancreatic intraepithelial neoplasia (PanIN) is a precursor to ductal adenocarcinoma.
  • But understanding precursor lesions in a pancreas with existing tumor is hampered by the fact that chronic pancreatitis often accompanies carcinoma, and the possible interactions between tumor, chronic pancreatitis, and PanIN are complex.
  • Heterotopic pancreas has a genetic make-up, physiologic function, and local environmental exposure similar to that of the pancreas.
  • We identified 6 pancreatic cancer patients who had heterotopic pancreas removed at the time of surgery.
  • Three of 6 cases harbored the same K-ras codon 12 mutation as the PanINs in orthotopic pancreas, and a similar pattern of p53, cyclin D1, and p16 expression was observed between heterotopic and orthotopic pancreas in all 6 cases.
  • The presence of PanIN in heterotopic pancreas from patients with ductal adenocarcinoma supports the progression model.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Choristoma / pathology. Duodenal Diseases / pathology. Pancreas. Pancreatic Neoplasms / pathology. Stomach Diseases / pathology


9. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


10. Vullierme MP, Giraud-Cohen M, Hammel P, Sauvanet A, Couvelard A, O'Toole D, Levy P, Ruszniewski P, Vilgrain V: Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability. Radiology; 2007 Nov;245(2):483-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability.
  • PURPOSE: To retrospectively evaluate computed tomographic (CT) findings in patients with in situ and invasive malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and to evaluate the accuracy for surgical resectability, with surgery and pathologic analysis as the reference standards.
  • CT findings were retrospectively evaluated to determine if a pancreatic malignant IPMN tumor was present; to make this determination, CT criteria were used to differentiate in situ from invasive tumors and signs of unresectability (liver metastasis, vascular CT pattern of encasement, or regional lymph node metastasis).
  • RESULTS: CT revealed a mural nodule in the pancreatic duct wall in 14 patients with in situ carcinoma and one patient with invasive carcinoma (P < .003).
  • CT revealed an infiltrative pancreatic mass in 17 patients with invasive carcinoma and two patients with in situ carcinoma (P < .02).
  • Of the mural nodules, 93% were seen in patients with in situ carcinoma, whereas 90% of infiltrative pancreatic masses were observed in patients with invasive carcinomas.
  • CONCLUSION: CT is helpful in the differentiation of in situ and invasive IPMN.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / radiography. Adenocarcinoma, Papillary / surgery. Adult. Aged. Female. Humans. Male. Preoperative Care / methods. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848678.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Carter RR, Woodall CE 3rd, McNally ME, Talboy GE, Lankachandra KM, Van Way CW 3rd: Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors. Am Surg; 2008 Apr;74(4):338-40
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for mixed ductal-endocrine carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ductal-endocrine carcinoma of the pancreas with synchronous papillary carcinoma-in-situ of the common bile duct: a case report and literature review--synchronous pancreatic and bile duct tumors.
  • This report is a case of a 58-year-old woman with a mixed ductal-endocrine carcinoma of the pancreas and a synchronous carcinoma-in-situ of the common bile duct.
  • Biopsies from this lesion showed adenocarcinoma.
  • Subsequently, pancreatoduodenectomy was performed for the diagnosis of peri-ampullary carcinoma.
  • Gross examination revealed a 2-cm irregular, ulcerated lesion obstructing the distal 0.5 cm of the common bile duct within the head of the pancreas.
  • On histopathological examination, it was discovered that this lesion contained two separate neoplasms: papillary carcinoma-in-situ of the intraparenchymal portion of the common bile duct and a mixed ductal-endocrine carcinoma of the pancreas.
  • Mixed ductal-endocrine carcinoma of the pancreas is very rare.
  • Finding it in conjunction with a synchronous, overlying papillary carcinoma carcinoma-in-situ of the common bile duct has not been previously described.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Common Bile Duct Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453301.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


12. Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg; 2008 Mar;12(3):401-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic neoplasia of the pancreas: pathology and biology.
  • In contrast with solid tumors, most of which are invasive ductal adenocarcinoma with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • While many are innocuous adenomas--in particular, those that are small and less complex, and in the case of IPMN, those that are branch-duct type are more commonly benign, some harbor or progress into in situ or invasive carcinomas.
  • The presence of ovarian-type stroma has now almost become a requirement for the diagnosis of MCN, and when defined as such, MCN is seen almost exclusively in women of perimenopausal age group as thick-walled multilocular cystic mass in the tail of the pancreas in contrast with IPMN which afflicts an elder population, both genders in almost equal numbers, and occur predominantly in the head of the organ.
  • In conclusion, cystic lesions in the pancreas constitute a biologically and pathologically diverse category most (but not all) of which are either benign or treatable diseases; however, a substantial subset, especially mucinous ones, has malignant potential that requires careful analysis.
  • [MeSH-major] Adenoma / pathology. Carcinoma in Situ / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Cystadenoma / pathology. Cystadenoma, Serous / pathology. Dilatation, Pathologic. Humans. Necrosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):61-6 [2909198.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):81-8 [10721809.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S71-93 [17486054.001]
  • [Cites] World J Surg. 2003 Mar;27(3):319-23 [12607059.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 17957438.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


13. Sanada Y, Masumoto T, Nishimura R: An in situ carcinoma of the pancreas forming 2 invasive ductal carcinomas. Pancreas; 2005 Aug;31(2):198-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An in situ carcinoma of the pancreas forming 2 invasive ductal carcinomas.
  • Histopathologically, the main lesion that obstructed the main pancreatic duct and measured 2.0 cm in diameter was a moderately differentiated adenocarcinoma with marked neural invasion.
  • The main pancreatic duct immediately distal to the tumor was lined with carcinoma in situ, and gradual transition from carcinoma in situ to mild atypia was observed.
  • The adjacent pancreatic contained carcinoma in situ and flat dysplastic cells without papillary growth.
  • We concluded that the structure of the cells lining the ducts and the comparatively flat formation and gradual transition indicated that 2 lesions, each invading the pancreatic parenchyma, arose from the intraductal tumor (carcinoma in situ or precancerous lesion).
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Pancreas / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025010.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Hara H, Suda K, Oyama T: Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas. Acta Cytol; 2005 Nov-Dec;49(6):611-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cytologic patterns in invasive ductal adenocarcinoma of the pancreas.
  • OBJECTIVE: To clarify 2 cytologic patterns: severe ductal dysplasia (SD)/carcinoma in situ (CIS) and invasive components of invasive ductal adenocarcinoma of the pancreas (IDAP).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450900.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, Tanaka M: Pancreatic juice cytology in IPMN of the pancreas. Pancreatology; 2005;5(4-5):416-21; discussion 421
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in IPMN of the pancreas.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a disease ranging from adenoma to borderline (with moderate dysplasia) and further to carcinoma (noninvasive and invasive) and surgical strategy is different by the grades of dysplasia.
  • In 4 patients with the 48 IPM adenomas, diagnosis of pancreatic juice cytology was class IV or V.
  • One of the 4 cases was considered to be an overdiagnosis of cytology, but the other 3 cases were considered to be a consequence of accompanying carcinoma in situ (or PanIN-3) (2 patients) or invasive ductal adenocarcinoma (1 patient) apart from IPMN.
  • When the diagnosis of pancreatic juice cytology is malignant in otherwise benign-looking IPMNs, coexistence of pancreatic carcinoma should be suspected.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Cytodiagnosis / methods. Pancreatic Juice / cytology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / classification. Adenoma / diagnosis. Aged. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15985766.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Adsay NV, Basturk O, Cheng JD, Andea AA: Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol; 2005 Oct;15(4):254-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
  • Invasive ductal adenocarcinoma (DA) is the most important and constitutes the vast majority (>85%) of pancreatic tumors.
  • A similar (in situ) neoplastic spectrum also characterizes intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, which are cystic ductal-mucinous tumors with varying degrees of papilla formation, and may be associated with invasive carcinoma.
  • Colloid carcinoma of the pancreas appears to be a clinicopathologically distinct tumor with indolent behavior.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Cystadenocarcinoma / pathology. DNA, Neoplasm. Gene Expression Regulation, Neoplastic. Gene Silencing. Genes, Neoplasm. Humans. Mutation. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Up-Regulation


17. Suda K, Nobukawa B, Yamasaki S, Abe K, Matsukuma S, Suzuki F: Invasive ductal adenocarcinoma of the pancreas may originate from the larger pancreatic duct: a study of 13 tumors less than 2 cm in diameter. J Hepatobiliary Pancreat Surg; 2007;14(3):283-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive ductal adenocarcinoma of the pancreas may originate from the larger pancreatic duct: a study of 13 tumors less than 2 cm in diameter.
  • BACKGROUND/PURPOSE: We aimed to elucidate the origin/primary site of invasive ductal adenocarcinoma of the pancreas, based on the distribution of intraductal carcinoma components.
  • METHODS: Thirteen specimens from patients with invasive ductal adenocarcinoma (microscopically, less than 2 cm in diameter) of the pancreas were studied histopathologically.
  • Variants of invasive ductal adenocarcinoma and intraductal papillary-mucinous carcinoma were excluded.
  • RESULTS: Intraductal carcinoma components of invasive ductal adenocarcinoma were found in 12 of the specimens 13 (92%), and were observed within the tumor mass and/or on its boundary, or outside the tumor mass.
  • CONCLUSIONS: Invasive ductal adenocarcinomas of the pancreas may originate most frequently from the main pancreatic duct or larger branch ducts, while the smaller ducts are less often the site of cancer origin.
  • [MeSH-minor] Adult. Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Retrospective Studies. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520204.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


18. Layfield LJ, Jarboe EA: Cytopathology of the pancreas: neoplastic and nonneoplastic entities. Ann Diagn Pathol; 2010 Apr;14(2):140-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of the pancreas: neoplastic and nonneoplastic entities.
  • Interpretation of cytologic material obtained from the pancreas is complex because of the large number of reactive processes and benign and malignant neoplasms arising within the pancreas.
  • Whereas separation of neuroendocrine, acinar, and ductal neoplasms is usually straightforward, the greatest diagnostic challenge in pancreatic fine-needle aspiration is the separation of atypical epithelium secondary to chronic pancreatitis from well-differentiated ductal adenocarcinoma.
  • Recently, a number of in situ lesions have been identified, complicating the cytologic diagnosis of pancreatic neoplasia.
  • [MeSH-major] Pancreas / pathology. Pancreatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227021.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


19. Lisovsky M, Dresser K, Woda B, Mino-Kenudson M: Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias. Hum Pathol; 2010 Jun;41(6):902-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for cell polarity protein lethal giant larvae 2 differentiates pancreatic intraepithelial neoplasia-3 and ductal adenocarcinoma of the pancreas from lower-grade pancreatic intraepithelial neoplasias.
  • Pancreatic intraepithelial neoplasia is a precursor to ductal adenocarcinoma of the pancreas that shows gastric differentiation.
  • Pancreatic intraepithelial neoplasia-3 has the highest potential to progress to adenocarcinoma, and its distinction from lower-grade pancreatic intraepithelial neoplasias is important for clinical management.
  • A product of cell polarity gene lethal giant larvae 2 is a marker of gastric foveolar epithelium expressed in a basolateral fashion, which is lost or mislocalized in gastric epithelial dysplasia and adenocarcinoma.
  • In this study, we investigated a role of lethal giant larvae 2 expression in differentiating low-grade pancreatic intraepithelial neoplasias, that is, pancreatic intraepithelial neoplasia-1 and pancreatic intraepithelial neoplasia-2, from pancreatic intraepithelial neoplasia-3 and pancreatic ductal adenocarcinoma.
  • Conversely, all lesions of pancreatic intraepithelial neoplasia-3 and adenocarcinoma showed loss of lethal giant larvae 2 staining and/or its cytoplasmic localization.
  • Loss or abnormal lethal giant larvae 2 expression is seen in pancreatic intraepithelial neoplasia-3 and adenocarcinoma and might be useful in separating them from lower-grade pancreatic intraepithelial neoplasias.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Cytoskeletal Proteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Cell Polarity. Diagnosis, Differential. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20233622.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


20. Kim YN, Park SY, Kim YK, Moon WS: Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ. J Korean Med Sci; 2010 Dec;25(12):1814-7
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ.
  • Pylorus-preserving pancreaticoduodenectomy was performed and diagnosis of XGP combined with intraductal papillary mucinous carcinoma in situ was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Granuloma / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis. Xanthomatosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Mar;28(3):254-7 [14961199.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):36-8 [15471123.001]
  • [Cites] Med Sci Monit. 2008 Nov;14(11):CS130-3 [18971878.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):704-7 [16120922.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):240-2 [18392724.001]
  • [Cites] Urology. 1994 Mar;43(3):295-9 [8134982.001]
  • (PMID = 21165301.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2995240
  • [Keywords] NOTNLM ; Cystic Tumor / Pancreas / Xanthogranulomatous Inflammation
  •  go-up   go-down


21. Fujii T, Kato K, Kodera Y, Kanda M, Nagai S, Yamada S, Kanzaki A, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakamura S, Nakao A: Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery; 2010 Aug;148(2):285-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas often recurs after operative resection.
  • The absolute risk and incidence of recurrence, however, especially in the remnant pancreas, is unknown.
  • METHODS: We reviewed our 18-year experience of 144 surgical cases of IPMNs and selected 103 cases of benign IPMN and carcinoma in situ (CIS) for analysis of the clinicopathologic features and long-term outcome of the recurrent disease, with particular emphasis on the status of the cut margins of the pancreas.
  • Recurrences in the remnant pancreas were observed in 9 cases: 4 (4.9%) among the 81 cases of benign IPMNs and 5 (22.7%) among the 22 cases of CIS.
  • The presence of adenoma had no influence on the outcome, and recurrence in the remnant pancreas was diagnosed in 5 (7.8%) of 64 adenoma-negative patients and 3 (10.7%) of 28 adenoma-positive patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pancreas / pathology. Prognosis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20434746.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Shimamoto F, Sueda T, Hiyama E: Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg; 2008 Jan;12(1):17-28; discussion 28-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has been increasingly identified as a precursor to infiltrating ductal adenocarcinoma.
  • We analyzed telomerase expression in 68 IPMN samples and assessed telomere length by quantitative fluorescence in situ hybridization in samples taken from 17 sequential IPMN patients that included 37 individual loci.
  • Marked telomere shortening was observed from the in situ IPMN carcinoma stage (P<0.001; vs borderline IPMNs) through the invasive stage, although telomerase had been activated, indicating that telomeres had shortened to a critical length by this histological grade.
  • Progressive telomere shortening predominantly occurs during early IPMNs carcinogenesis before telomerase activation and progression from borderline to carcinoma in situ IPMNs is the critical stage of IPMNs carcinogenesis at which telomere dysfunction occurs.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / pathology. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme Activation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Telomere / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):365-72 [12105864.001]
  • [Cites] Oncogene. 1995 Mar 2;10(5):937-44 [7898935.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):972-9 [15280920.001]
  • [Cites] Surgery. 2006 Sep;140(3):448-53 [16934608.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Nature. 1997 Feb 20;385(6618):740-3 [9034193.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):619-26 [11850787.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9623-7 [16266979.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6405-9 [12438224.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1271-4 [9359704.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):474-9 [12717449.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] EMBO J. 1992 May;11(5):1921-9 [1582420.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):16-30 [10721804.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):641-5 [10949306.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1259-68 [11943711.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • [Cites] Science. 1997 Aug 15;277(5328):955-9 [9252327.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):17-26 [11326312.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):643-9 [11850791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8191-6 [12034875.001]
  • [Cites] Eur J Cancer. 1997 Apr;33(5):787-91 [9282118.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):277-83 [12579258.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4833-40 [15256453.001]
  • [Cites] Science. 1998 Jan 16;279(5349):349-52 [9454332.001]
  • [Cites] Science. 2002 Jul 26;297(5581):565-9 [12142527.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3317-26 [15161685.001]
  • (PMID = 17960465.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


23. Liang S, Yang ZL: [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb;32(1):109-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats].
  • METHODS: Dimethylbenzanthracene (DMBA) was directly implanted into the parenchyma of pancreas in SD rats (Group A), and DMBA combined with trichostatin (TSA) was implanted in the intervention group (Group B).
  • The expression of KiSS-1mRNA was assayed by in situ hybridization. RESULTS:.
  • (1) The incidence of pancreatic cancer in Group A within 3 - 5 months was 48.7% (18/37), including 17 cases of pancreatic ductal adenocarcinoma and 1 case of fibrosarcoma.
  • The incidence of pancreatic cancer in Group B was 33.3% (12/36), including 11 pancreatic ductal adenocarcinoma and 1 fibrosarcoma.
  • The positive rates of KiSS-1mRNA in Group A or Group B with ductal adenocarcinoma were significantly lower than those in Group A or Group B without ductal adenocarcinoma (P<0.01).
  • CONCLUSION: DMBA directly implanted into the parenchyma of pancreas can obtain an ideal pancreatic cancer model with high incidence in a short time.
  • TSA may have an inhibitive effect on the carcinogenesis and the growth of pancreatic ductal adenocarcinoma in rats, and KiSS-1 may play an important role in inhibiting the invasion and metastasis of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Pancreas / metabolism. Pancreatic Neoplasms / genetics. Proteins / genetics
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Female. Gene Expression Regulation, Neoplastic. In Situ Hybridization. Kisspeptins. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Random Allocation. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344598.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Kiss1 protein, rat; 0 / Kisspeptins; 0 / Proteins; 0 / RNA, Messenger; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


24. Reuss R, Aberle S, Klingel K, Sauter M, Greschniok A, Franke FE, Padberg W, Blin N: The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas. Int J Oncol; 2006 Sep;29(3):649-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the carboxyl ester lipase gene in pancreas and pancreatic adenocarcinomas.
  • Twenty-five tumor samples, 24 samples of normal pancreatic tissue and control tissues from other organs were examined by radioactive in situ hybridization (ISH) to localize CEL mRNA.
  • By ISH, we verified a strong CEL gene expression in acinar cells of the normal pancreas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Regulation, Enzymologic / physiology. Lipase / genetics. Pancreas / enzymology. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / genetics. Carcinoma, Acinar Cell / enzymology. Carcinoma, Acinar Cell / genetics. Carcinoma, Pancreatic Ductal / enzymology. Carcinoma, Pancreatic Ductal / genetics. Humans. In Situ Hybridization. Liver Neoplasms / enzymology. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Pancreatitis / enzymology. Pancreatitis / genetics. RNA Probes. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865281.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA Probes; 0 / RNA, Messenger; EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  •  go-up   go-down


25. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • The aim of this study was to identify useful preoperative diagnostic findings indicative of malignant or invasive intraductal papillary-mucinous neoplasms (IPMN) of the pancreas to determine an optimal operative procedure for IPMN.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):163-71 [9196015.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Surgery. 1997 Sep;122(3):617-25 [9308621.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):967-71 [11490850.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):900-5 [9041151.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):962-6 [11490849.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):35-41 [11148557.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1041-7 [10931048.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):826-33 [8039110.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):117-21 [12622422.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):277-83 [12579258.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1429-34 [11374678.001]
  • [Cites] Surgery. 2001 Jan;129(1):55-65 [11150034.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Wendt LR, Osvaldt AB, Bersch VP, Schumacher Rde C, Edelweiss MI, Rohde L: Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine. Acta Cir Bras; 2007 May-Jun;22(3):202-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice: effects of alcohol and caffeine.
  • In all animals, 1 mg of DMBA was implanted into the head of the pancreas.
  • After 30 days, euthanasia was performed; excised pancreata were then fixed in formalin, stained with hematoxylin-eosin and categorized as follows: normal ducts, reactive hyperplasia, PanIN-1A, PanIN-1B, PanIN-2, PanIN-3 or adenocarcinoma.
  • Adenocarcinoma was detected in 15% of animals in the caffeine group, 16.6% in the water group, 23.8% in the alcohol + caffeine group and 52.9% in the alcohol group (P<0.05).
  • CONCLUSIONS: The experimental pancreatic carcinogenesis mouse model using DMBA effectively induces PanIN lesions and pancreatic adenocarcinoma.
  • This study verified the association between alcohol use and pancreatic adenocarcinoma; caffeine did not present the same effect.

  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546293.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Carcinogens; 3G6A5W338E / Caffeine; 3K9958V90M / Ethanol; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


27. Schnelldorfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, Chari ST, Farnell MB: Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg; 2008 Jul;143(7):639-46; discussion 646
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
  • HYPOTHESIS: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized disease of the pancreas.
  • RESULTS: Of 208 patients (mean age, 66 years) with IPMN of the pancreas, 168 underwent partial pancreatectomy, and 40 underwent total pancreatectomy; 88 were classified as having adenoma, 38 as having borderline neoplasm, 19 as having carcinoma in situ, and 63 as having invasive carcinoma.
  • Patients with invasive IPMN had a similar 5-year survival compared with a matched cohort with ductal adenocarcinoma (31% vs 24%; P = .26).
  • Invasive IPMN behaves as aggressively as ductal adenocarcinoma, but resection seems to provide the only potential for cure.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645105.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Watanabe Y, Horiuchi A, Sato K, Yukumi S, Sugishita H, Yoshida M, Doi T, Yamamoto Y, Ishida N, Kameoka K, Kawachi K: Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case. Surg Today; 2010 May;40(5):465-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous intraductal papillary mucinous neoplasm with carcinoma in situ of the pancreas arising within a short interval: report of a case.
  • A 61-year-old man with an intraductal papillary mucinous neoplasm (IPMN) and carcinoma in situ (CIS) of the pancreatic body initially underwent a distal pancreatectomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma in Situ / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Gastroenterology. 1991 Aug;101(2):512-9 [1648527.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):576-89 [7726368.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 1999 Feb;177(2):117-20 [10204552.001]
  • [Cites] Am Surg. 2001 May;67(5):400-6 [11379635.001]
  • [Cites] Surg Today. 2008;38(4):371-6 [18368332.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):564-9 [8385881.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • (PMID = 20425552.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Ovary / cytology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Osvaldt AB, Wendt LR, Bersch VP, Backes AN, de Cássia A Schumacher R, Edelweiss MI, Rohde L: Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice. Surgery; 2006 Nov;140(5):803-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice.
  • BACKGROUND: Pancreatic ductal adenocarcinoma has a poor long-term prognosis.
  • METHODS: Ninety male, Mus musculus, CF-1 mice underwent a median laparotomy and 1 mg of DMBA was implanted into the proximal pancreas held in place by a purse-string suture.
  • The specimens were evaluated blind by 2 pathologists for the presence of the following histology: normal ducts, reactive hyperplasia, PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3, and adenocarcinoma.
  • All pancreata with adenocarcinoma had concomitant PanIN lesions.
  • CONCLUSIONS: The DMBA experimental model in mice induces PanIN lesions and ductal adenocarcinoma that have similar histology to that of human pancreatic cancer.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene. Carcinoma in Situ / chemically induced. Carcinoma, Pancreatic Ductal / chemically induced. Disease Models, Animal. Pancreatic Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084724.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


31. Hara H, Suda K: Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma. Am J Clin Pathol; 2008 Jan;129(1):115-29
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
  • Invasive ductal adenocarcinoma (IDA) of the pancreas (IDAP) originating from the ductal gland has a poor prognosis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Hyperplasia / pathology. Mucins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089497.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


32. Corvera CU, Dunnican WJ, Blumgart LH, D'Angelica M: Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature. Pancreas; 2006 Apr;32(3):321-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent invasive intraductal papillary mucinous carcinoma of the pancreas mimicking pott disease: review of the literature.
  • We report an unusual case of cancer recurrence in an 86-year-old woman who had undergone a pancreaticoduodenectomy for a large IPMN in the head of the pancreas.
  • Final pathological evaluation of the resected pancreas found a component of in situ and invasive ductal adenocarcinoma without lymph node involvement.
  • Nine years later, the patient developed a retroperitoneal psoas abscess that was misdiagnosed as tuberculous spondylitis (Pott disease) but was proven to be recurrent mucinous adenocarcinoma of pancreatic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasm Recurrence, Local / pathology. Pancreatic Neoplasms / pathology. Tuberculosis, Spinal / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628089.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, Hruban RH, Goggins M: Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol; 2008 Dec;21(12):1499-507
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.
  • Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer death and is usually diagnosed late.
  • Intraductal papillary mucinous neoplasms are an increasingly recognized precursor to invasive ductal adenocarcinoma of the pancreas.
  • Normal pancreas was also obtained from 27 patients with intraductal papillary mucinous neoplasms or pancreatic adenocarcinomas and 10 patients with well-differentiated pancreatic endocrine neoplasms.
  • Carcinomas (intraductal papillary mucinous neoplasms with carcinoma in situ or their associated infiltrating adenocarcinoma) had significantly more methylated genes (71+/-19%) than low-grade (low and moderate dysplasia) intraductal papillary mucinous neoplasms (44+/-26%, P<0.0001).
  • The detection of aberrant methylation in pancreatic cystic lesions could facilitate the diagnosis of intraductal papillary mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):548-65 [16472607.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):365-72 [12105864.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5 [17481526.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6019-25 [17947463.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):863-9 [17899180.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):243-9 [18027059.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):850-8 [15592528.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):573-83 [15701843.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • (PMID = 18820670.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-140011; United States / NCI NIH HHS / CA / CA062924-149002; United States / NCI NIH HHS / CA / CA062924-150011; United States / NCI NIH HHS / CA / P50 CA062924-149002; United States / NCI NIH HHS / CA / P50 CA062924-159002; United States / NCI NIH HHS / CA / P50 CA062924-150011; United States / NCI NIH HHS / CA / CA062924-159002; United States / NCI NIH HHS / CA / CA062924-140011
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  • [Other-IDs] NLM/ NIHMS105558; NLM/ PMC2678809
  •  go-up   go-down


34. Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB: Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer; 2006 Jun 25;108(3):163-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
  • BACKGROUND: Intraductal papillary mucinous neoplasm (IPMN) is an increasingly recognized cystic neoplasm of the pancreas, histologically classified by the degree of epithelial atypia and by the presence or absence of invasion of the cyst wall.
  • These cytologic features were subsequently correlated with the histologic diagnosis.
  • Necrosis distinguished IPMN with carcinoma from IPMN-adenomas and IPMN with moderate dysplasia (P < .00001), and was more often observed with invasion than IPMN-carcinoma in situ (P < .05).
  • Pale nuclei with parachromatin clearing was found to be a nuclear feature that was suspicious for at least carcinoma in situ (P < .001).
  • In addition, significant background inflammation (neutrophils and histiocytes) was found to be more characteristic of IPMN with at least carcinoma in situ (P = .002).
  • The presence of tight epithelial cell clusters is consistent with a neoplasm of at least moderate dysplasia, and abundant background inflammation and parachromatin clearing correlated with the presence of at least carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Mucins / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550572.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


35. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol; 2007 Jun;20(6):656-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
  • Here we sought to determine if the proinvasive integrin alpha6beta4 may be related to pancreatic adenocarcinoma tumor progression.
  • Expression of integrin alpha6beta4 was analyzed via immunohistochemistry for the beta4 subunit in normal pancreas, pancreatic intraepithelial neoplasia (PanIN) lesions, pancreatic adenocarcinomas and chronic pancreatitis.
  • In contrast, 93% (13/14) of chronic pancreatitis samples resembled the staining pattern of normal pancreas.
  • We conclude that integrin alpha6beta4 is expressed only on the basal surface of ductal cells in normal pancreas and chronic pancreatitis.
  • During pancreatic adenocarcinoma progression, the alpha6beta4 integrin is dramatically overexpressed and displays altered localization at the earliest stages of PanIN, thus representing an early event in pancreatic adenocarcinoma progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415382.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
  • [Other-IDs] NLM/ NIHMS517144; NLM/ PMC4697742
  •  go-up   go-down


36. Beger HG, Gansauge F, Siech M, Schwarz M, Poch B: Duodenum-preserving total pancreatic head resection for cystic neoplastic lesions in the head of the pancreas. J Hepatobiliary Pancreat Surg; 2008;15(2):149-56
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-preserving total pancreatic head resection for cystic neoplastic lesions in the head of the pancreas.
  • BACKGROUND/PURPOSE: Cystic neoplastic lesions of the pancreas are now found with increasing frequency.
  • We report the following data from 15 patients treated surgically for cystic neoplastic lesions of the pancreas head.
  • Ten patients suffered cystadenoma, three patients had a borderline lesion, and two patients had an in-situ carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Cysts / surgery. Duodenum / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392707.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. A-Cienfuegos J, Rotellar F, Martí-Cruchaga P, Valentí V, Zozaya G, Bueno A, Pedano N, Lozano MD, Sola JJ, Pardo F: Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Rev Esp Enferm Dig; 2010 May;102(5):314-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results.
  • Several atypia (IPMN carcinoma in situ) was observed in 2 patients and invasive carcinoma with negative lymph nodes was identified in 3 patients.
  • A patient without invasive carcinoma died at 66 months of follow-up for pancreas adenocarcinoma.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Pancreas / pathology. Pancreas / surgery. Pancreaticoduodenectomy. Postoperative Period. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524759.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP, Barbacid M: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell; 2007 Mar;11(3):291-302
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.
  • Pancreatic ductal adenocarcinoma (PDA), one of the deadliest human cancers, often involves somatic activation of K-Ras oncogenes.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Genes, ras. Pancreatic Neoplasms / pathology. Pancreatitis, Chronic / pathology
  • [MeSH-minor] Animals. Cell Lineage. Cell Transformation, Neoplastic. Ceruletide. Doxycycline / pharmacology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Mice. Mice, Mutant Strains. Mutation. Neoplasm Invasiveness. Pancreas / pathology. Signal Transduction


39. Katabi N, Klimstra DS: Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J Clin Pathol; 2008 Dec;61(12):1303-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach.
  • In addition, IPMNs sometimes can be confused with other primary cystic lesions of the pancreas.
  • As a result, the correct diagnosis of IPMN can be challenging.
  • This review addresses the clinical and pathological features of IPMNs, emphasising their diagnostic criteria, differential diagnosis and biological behaviour.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma in Situ / diagnosis. Diagnosis, Differential. Humans. Neoplasm Invasiveness. Pancreatectomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18703569.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 73
  •  go-up   go-down


40. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA: Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther; 2005 Mar;4(3):302-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype.
  • Using nonradioactive in situ hybridization, we evaluated the gene expression patterns of three genes previously shown to be robust markers of the juxtatumoral stroma within eight infiltrating ductal adenocarcinoma of the pancreas (ApoC1, ApoD and MMP11), and compared these patterns to those associated with seven infiltrating colloid and tubular carcinomas arising in association with intraductal papillary mucinous neoplasms (IPMNs), a histologically distinct form of primary carcinoma of the pancreas, two surgically resected samples of chronic pancreatitis and two surgically resected pancreatic cancer liver metastases.
  • Robust juxtatumoral stromal expression was noted for all three markers within all eight conventional infiltrating ductal adenocarcinoma tissues, but not in samples of chronic pancreatitis.
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Apolipoprotein C-I. Apolipoproteins / analysis. Apolipoproteins / genetics. Apolipoproteins C / analysis. Apolipoproteins C / genetics. Apolipoproteins D. Carcinoma, Pancreatic Ductal / chemistry. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / secondary. Cell Communication / genetics. Gene Expression. Glycoproteins / analysis. Glycoproteins / genetics. Humans. In Situ Hybridization. Liver Neoplasms / chemistry. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Matrix Metalloproteinase 11. Membrane Transport Proteins / analysis. Membrane Transport Proteins / genetics. Metalloendopeptidases / analysis. Metalloendopeptidases / genetics. RNA, Messenger / analysis. RNA, Messenger / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876873.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA1066110; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APOD protein, human; 0 / Apolipoprotein C-I; 0 / Apolipoproteins; 0 / Apolipoproteins C; 0 / Apolipoproteins D; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


41. Lee SH, Park JK, Woo SM, Yoo JW, Ryu JK, Kim YT, Yoon YB: [Natural history of branch-duct type intraductal papillary mucinous neoplasms of the pancreas]. Korean J Gastroenterol; 2007 Jan;49(1):24-30
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of branch-duct type intraductal papillary mucinous neoplasms of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are consisted of two types; branch-duct type and main-duct type.
  • Ten patients underwent surgical resection and pathologic examination revealed one carcinoma in situ and one invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2007 Jan;49(1):50-2 [18167435.001]
  • (PMID = 18167430.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


42. Krishnasamy R, Agarwal S, Singh S, Puri S, Sakhuja P, Agarwal AK: Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case. Hepatobiliary Pancreat Dis Int; 2007 Oct;6(5):553-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia: report of a case.
  • BACKGROUND: The presence of pancreatic ductal intraepithelial neoplasia in patients with chronic pancreatitis is a risk factor for development of pancreatic adenocarcinoma.
  • METHOD: A case of pancreatic ductal adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia was diagnosed in the setting of chronic pancreatitis.
  • RESULTS: Distal pancreatectomy combined with splenectomy was performed with a diagnosis of pancreatic body carcinoma.
  • Histopathological examination suggested adenocarcinoma associated with pancreatic ductal intraepithelial neoplasia.
  • The tumor was detected in the remaining head of the pancreas, for which a total pancreatectomy was done.
  • CONCLUSIONS: When a patient with pancreatic ductal intraepithelial neoplasia associated with adenocarcinoma of the pancreas in the setting of chronic pancreatitis is at an increased risk of recurrence in the remaining pancreatic parenchyma, total pancreatectomy may be feasible.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Laparoscopy. Laparotomy / methods. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Multiple Primary. Pancreatectomy / methods. Splenectomy / methods. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatobiliary Pancreat Dis Int. 2008 Feb;7(1):106-7 [18234650.001]
  • (PMID = 17897923.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Mansour JC, Schwartz L, Pandit-Taskar N, D'Angelica M, Fong Y, Larson SM, Brennan MF, Allen PJ: The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg; 2006 Dec;10(10):1354-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas.
  • Previous studies have suggested that whole body positron-emission tomography (PET) can distinguish between benign and malignant cysts of the pancreas.
  • Patients were identified (n = 68) who had undergone whole body PET imaging for a cystic lesion of the pancreas between Jan.
  • Within the resected group of patients (n=21), four of the seven patients (57%) with either in situ or invasive malignancy (adenocarcinoma: 3 of 5, papillary mucinous carcinoma: 1 of 2) had positive PET imaging (mean SUV, 5.9; range 2.5-8.0), and 2 of the 14 patients (14%) with benign lesions had positive PET imaging (serous cystadenoma, n=1, SUV=3.3; pseudocyst n=1, SUV=2.7).
  • We do not believe whole body FDG-PET to be essential in the evaluation of cystic lesions of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Adenocarcinoma, Mucinous / diagnostic imaging. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Surgery. 2005 Oct;138(4):672-9; discussion 679-80 [16269296.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Jun;3(6):461-3 [16167022.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Langenbecks Arch Surg. 1998 Mar;383(1):56-61 [9627172.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):970-7 [14675706.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):675-80 [11685032.001]
  • [Cites] Radiology. 2000 Dec;217(3):757-64 [11110940.001]
  • [Cites] Surgery. 2002 Oct;132(4):628-33; discussion 633-4 [12407346.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):1007-9; discussion 1009 [16530543.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Cancer Treat Rev. 2005 Nov;31(7):507-35 [16257126.001]
  • (PMID = 17175454.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


44. Witkiewicz AK, Kennedy EP, Kennyon L, Yeo CJ, Hruban RH: Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Hum Pathol; 2008 Oct;39(10):1548-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature.
  • Histologic evaluation of the specimen revealed synchronous autoimmune pancreatitis (lymphoplasmacytic sclerosing pancreatitis) and infiltrating ductal adenocarcinoma of the pancreas.
  • Although not appreciated grossly, pancreatic intraepithelial neoplasia-3 and a neurotropic infiltrating poorly differentiated adenocarcinoma of the pancreas were also present.
  • [MeSH-major] Autoimmune Diseases / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Pancreatitis / pathology


45. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK: MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol; 2006 Mar;186(3):687-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate factors predictive of the presence of invasive carcinoma associated with intraductal papillary mucinous neoplasm (IPMN) of the pancreas on MDCT.
  • MATERIALS AND METHODS: Preoperative MDCT of 36 consecutive patients (23 men, 13 women; mean age, 66.6 years) who had undergone surgical resection and had a pathologic diagnosis of IPMN were retrospectively assessed.
  • RESULTS: Pathologic analysis revealed carcinoma in situ in seven patients (19%) and invasive carcinoma in 15 patients (42%) arising from the IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498096.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


46. Goh BK, Ooi LL, Kumarasinghe MP, Tan YM, Cheow PC, Chow PK, Chung YF, Wong WK: Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology; 2006;6(6):520-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm.
  • BACKGROUND/AIMS: The occurrence of concomitant pancreatic endocrine neoplasm (PEN) and intraductal papillary neoplasm (IPMN) of the pancreas has rarely been reported.
  • The IPMNs were found in the tail (n = 4), head (n = 3), head and body (n = 1), body (n = 1) and the entire pancreas (n = 1).
  • Five of these neoplasms were benign, 2 were borderline and 3 were malignant (1 carcinoma in situ).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel and IAP.
  • (PMID = 17124434.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


47. Körner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC: Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am J Pathol; 2005 Oct;167(4):959-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia.
  • Because the receptors for the gut hormone secretin are poorly characterized, we assessed secretin receptor expression in the main secretin target, the human pancreas.
  • Secretin receptors were highly expressed in non-neoplastic ducts and lobuli and also in lower amounts in ductal neoplasias, including ductal adenocarcinoma, intraductal papillary mucinous tumors, and pancreatic intraepithelial neoplasia.
  • Reverse transcriptase-polymerase chain reaction revealed wild-type receptor mRNA in the non-neoplastic pancreas and both wild-type and spliced variant receptor transcripts in ductal adenocarcinomas.
  • This study is the first to describe the precise secretin receptor distribution in human non-neoplastic pancreas and various pancreatic tumors.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Pancreas / metabolism. Pancreatic Neoplasms / metabolism. Receptors, G-Protein-Coupled / metabolism. Receptors, Gastrointestinal Hormone / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Alternative Splicing. Animals. Autoradiography. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Humans. Iodine Radioisotopes. Pancreatic Ducts / metabolism. RNA, Messenger / genetics. Rats

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1998 Mar;184(3):234-9 [9614373.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):382-97 [9453500.001]
  • [Cites] Am J Physiol. 1998 Dec;275(6 Pt 1):G1437-44 [9843782.001]
  • [Cites] Endocrine. 1998 Oct;9(2):171-83 [9867251.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):G487-94 [10444464.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3105-12 [10850463.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Dig Dis. 2001;19(1):15-23 [11385247.001]
  • [Cites] J Membr Biol. 2001 Sep 15;183(2):71-84 [11562789.001]
  • [Cites] Genome Biol. 2001;2(12):REVIEWS3013 [11790261.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):500-11 [11832464.001]
  • [Cites] J Nucl Med. 2002 May;43(5):610-6 [11994522.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5223-9 [12234988.001]
  • [Cites] Pharmacol Rev. 2003 Mar;55(1):167-94 [12615957.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):389-427 [12920149.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1649-54 [14530481.001]
  • [Cites] J Gastroenterol. 2003;38(11):1025-35 [14673718.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Oct 30;102(4):1336-41 [6274336.001]
  • [Cites] J Histochem Cytochem. 1982 Sep;30(9):864-73 [6813372.001]
  • [Cites] Am J Physiol. 1984 Jun;246(6 Pt 1):G710-7 [6204536.001]
  • [Cites] Cell Tissue Res. 1985;242(3):633-9 [2416452.001]
  • [Cites] Peptides. 1987 Jul-Aug;8(4):633-7 [2819833.001]
  • [Cites] Pancreas. 1988;3(5):529-35 [3186683.001]
  • [Cites] Gastroenterology. 1989 Jun;96(6):1439-44 [2565843.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):713-22 [2572194.001]
  • [Cites] Int J Pancreatol. 1989 Sep;5(2):191-201 [2600453.001]
  • [Cites] Gastroenterology. 1990 Jun;98(6):1666-74 [2186957.001]
  • [Cites] J Biol Chem. 1991 Jan 5;266(1):316-22 [1702423.001]
  • [Cites] EMBO J. 1991 Jul;10(7):1635-41 [1646711.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G805-10 [8238510.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Feb 27;207(3):883-90 [7864894.001]
  • [Cites] Mol Pharmacol. 1995 Mar;47(3):467-73 [7700244.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):26-34 [8644985.001]
  • [Cites] Br J Cancer. 1997;75(10):1467-73 [9166939.001]
  • [Cites] Gut. 1998 Apr;42(4):546-50 [9616318.001]
  • (PMID = 16192632.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Gastrointestinal Hormone; 0 / secretin receptor
  • [Other-IDs] NLM/ PMC1603664
  •  go-up   go-down


48. Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, Borner M, Diamantis I, Zimmermann A, Terracciano L: Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN). Pathology; 2010 Apr;42(3):229-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • RESULTS: Our study revealed a differential p27, p21, p53, and Ki-67 expression between ductal adenocarcinoma, PanIN-3 and normal pancreas. p27 expression progressively decreased from normal pancreas to PanIN and to pancreatic cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cell Cycle Proteins / biosynthesis. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350215.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


49. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH: PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
  • PURPOSE: The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis.
  • RESULTS: The PAM4-reactive MUC1 epitope was not detected in normal pancreas but was expressed in 87% (48 of 55) of invasive pancreatic adenocarcinomas, including early stage 1 disease: PAM4 labeled 94% (44 of 47) of the earliest PanIN lesions, PanIN-1A and 1B, along with 91% (10 of 11) of PanIN-2, 40% (2 of 5) of PanIN-3, and 86% (31 of 36) of intraductal papillary mucinous neoplasia lesions.
  • A second, unrelated, anti-MUC1 MAb, MA5, showed considerably less sensitivity with early PanIN-1 lesions; only 61% (25 of 41) were positive and the labeling did not differentiate normal pancreas from PanINs.
  • CONCLUSIONS: The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1.
  • Detection of this biomarker using immunohistology, in vitro immunoassays, and in vivo antibody-based imaging may provide new opportunities for the early detection and improved diagnosis of pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Mucin-1 / metabolism. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Aug 15;14(16):5306; author reply 5306-7 [18698052.001]
  • (PMID = 18094420.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096924; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Mucin-1
  •  go-up   go-down


50. Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist; 2010;15(12):1294-309
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.
  • Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas.
  • For a long time they were misdiagnosed as mucinous cystadenocarcinoma, ductal adenocarcinoma in situ, or chronic pancreatitis.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2004 Oct;29(3):212-7 [15367887.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Dig Surg. 2008;25(1):46-51 [18292661.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1127-32 [18299945.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):474-81 [17680299.001]
  • [Cites] Pancreatology. 2008;8(3):277-84 [18497541.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):802-7 [18716113.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41 [18843017.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3187-92 [18766406.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):543-7 [12297771.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):234-42 [18040749.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3193-8 [18784959.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1499-507 [18820670.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S203-9 [19179158.001]
  • [Cites] Pancreas. 2009 Mar;38(2):131-6 [18981954.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pathologe. 2005 Feb;26(1):22-30 [15624092.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4681-8 [16000561.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1034-42 [15832194.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):112-6 [16639605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 [16858538.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Pancreatology. 2006;6(6):626-34 [17135772.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] JOP. 2007;8(2):206-13 [17356245.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95 [17350894.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(1):35-48 [19258185.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Pancreatology. 2009;9(1-2):34-44 [19077453.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] Radiology. 2009 Oct;253(1):106-15 [19703865.001]
  • [Cites] Pancreatology. 2009;9(5):631-8 [19657218.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):531-40 [19818780.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):477-82 [20142730.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Pancreas. 2010 Apr;39(3):308-14 [19924021.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Langenbecks Arch Surg. 2003 Dec;388(6):392-400 [12910422.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • (PMID = 21147870.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227924
  •  go-up   go-down


51. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma. Semin Oncol; 2006 Dec;33(6 Suppl 11):S50-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The angiogenic switch molecule, secreted FGF-binding protein, an indicator of early stages of pancreatic and colorectal adenocarcinoma.
  • We will discuss genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis.
  • Histochemical and in situ hybridization studies with archival samples show that FGF-BP is induced early during the initiation of colorectal and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] J Clin Invest. 1999 Aug;104(3):263-9 [10430607.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] Curr Opin Genet Dev. 1999 Oct;9(5):595-603 [10508699.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):747-55 [15806140.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jul;55(1):67-81 [15890525.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R105-13 [16352855.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):1137-44 [16257968.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1191-8 [16424058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):361-81 [10666364.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Clin Exp Immunol. 2000 Apr;120(1):59-65 [10759764.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):230-3 [10777178.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Endocr Relat Cancer. 2000 Sep;7(3):165-97 [11021964.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10263-71 [11148217.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):40247-53 [11509569.001]
  • [Cites] Oncology (Williston Park). 2001 Oct;15(10):1241-9, 1254; discussion 1254-64 [11702956.001]
  • [Cites] Gut. 2002 Jul;51(1):56-9 [12077092.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):301-13 [12105858.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Cytokine. 2002 Nov 24;20(4):184-90 [12543084.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1696-705 [12670924.001]
  • [Cites] Pancreas. 2003 May;26(4):344-9 [12717266.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):722-33 [12900362.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8085-9 [14678957.001]
  • [Cites] Pancreas. 2004 Jan;28(1):25-30 [14707726.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Jun;13(6):631-41 [15174949.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:8 [12556241.001]
  • [Cites] Trends Genet. 2004 Nov;20(11):563-9 [15475116.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16778-85 [1885605.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5289-96 [7693336.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1731-4 [8259518.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1734-7 [8259519.001]
  • [Cites] Genomics. 1994 Feb;19(3):525-31 [8188295.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2043-50 [7931472.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5953-8 [7954428.001]
  • [Cites] J Biol Chem. 1994 Nov 11;269(45):28243-8 [7525570.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3046-50 [7708772.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):309-15 [7575607.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):843-8 [8922199.001]
  • [Cites] J Pathol. 1996 Dec;180(4):364-70 [9014855.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):390-5 [9139874.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2671-81 [9178765.001]
  • [Cites] Biochim Biophys Acta. 1997 Jun 7;1332(3):F127-47 [9196022.001]
  • [Cites] Curr Biol. 1997 Jul 1;7(7):R443-6 [9210368.001]
  • [Cites] Oncogene. 1997 Sep 18;15(12):1417-24 [9333017.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1137-40 [9334727.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):798-807 [9516401.001]
  • [Cites] Pancreas. 1998 Aug;17(2):169-75 [9700949.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Kidney Int Suppl. 1998 Sep;67:S3-6 [9736244.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):765-70 [9743297.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1395-413 [9779987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;237:97-132 [9893348.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):383-91 [9931387.001]
  • (PMID = 17178288.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL068686; United States / NCI NIH HHS / CA / R01 CA071508; United States / NCI NIH HHS / CA / R01 CA108440; United States / NCI NIH HHS / CA / R01 CA71508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139946-12-6 / FGFBP1 protein, human
  • [Number-of-references] 98
  • [Other-IDs] NLM/ NIHMS15609; NLM/ PMC1781498
  •  go-up   go-down


52. Huo Z, Yang D, Chang XY, Wan JW, Chen J: [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):670-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases].
  • OBJECTIVE: To study the clinicopathologic features and diagnosis of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • It affected patients in older age group (mean age = 59) and was located mainly in the head of pancreas (60%).
  • Features of in-situ or invasive malignancy were present in 15 of the 19 cases (78%).
  • The prognosis after surgical resection however is better than that of conventional pancreatic adenocarcinoma.
  • Early recognition by radiologic examination (including ERCP) and pancreatic cytology would be helpful in early diagnosis.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / analysis. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Cell Cycle Proteins / analysis. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pancreatectomy. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Prognosis. Receptor, ErbB-2 / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094485.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CDCA5 protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


53. Yamaguchi T, Shirai Y, Ishihara T, Sudo K, Nakagawa A, Ito H, Miyazaki M, Nomura F, Saisho H: Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy. Cancer; 2005 Dec 15;104(12):2830-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
  • BACKGROUND: The examination of pancreatic juice cytology could hypothetically contribute to the establishment of a definite diagnosis of malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN), but to the authors' knowledge, its significance has not been confirmed to date.
  • METHODS: The study subjects were comprised of 103 patients with IPMN who underwent surgical resection of pancreatic tumors (adenoma in 29 patients, borderline in 17 patients, carcinoma in situ in 25 patients, and invasive carcinoma in 32 patients).
  • RESULTS: The cytologic diagnosis was found to be of nondiagnostic value in only one patient with an IPMN, whereas it was of no diagnostic value in 14 of the patients with pancreatic carcinoma (17.3%), a difference that was statically significant (P < 0.001).
  • The location of the IPMN (either in the pancreas or the pancreatic ducts) was not found to significantly affect the diagnostic value of the test.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Juice / cytology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Endoscopic Retrograde / methods. Cohort Studies. Cytodiagnosis / methods. Diagnosis, Differential. Endoscopy, Digestive System / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reference Values. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16287152.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis; 2008 Jun;29(6):1096-107
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
  • Thus, simultaneous inhibition of both tyrosine kinases represents a potential novel therapeutic approach in human pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 [8832401.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):793-9 [8707856.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7162-8 [9507031.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2571-85 [9566877.001]
  • [Cites] Trends Cell Biol. 1998 Apr;8(4):151-7 [9695829.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):547-60 [9786962.001]
  • [Cites] Cell Growth Differ. 1998 Dec;9(12):999-1005 [9869300.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5422-8 [10026153.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3868-76 [15867386.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):505-15 [16069815.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6 [16360004.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1446-54 [16452200.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 [16549325.001]
  • [Cites] Biochem Pharmacol. 2006 May 14;71(10):1435-48 [16530734.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):787-96 [16648548.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1357-67 [17431114.001]
  • [Cites] Exp Cell Res. 1996 Feb 1;222(2):298-303 [8598217.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38978-87 [12167618.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Dec;35(4):353-8 [12378529.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3846-51 [12458213.001]
  • [Cites] Cell Signal. 2003 Jun;15(6):575-83 [12681445.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1001-11 [12937141.001]
  • [Cites] Mol Cancer Res. 2003 Aug;1(10):755-64 [12939401.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92 [14623342.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):559-67 [14629195.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4361-71 [15121855.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2007-11 [7743492.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Mar 27;220(3):886-90 [8607861.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):413-8 [9052982.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):249-56 [10806474.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2417-23 [10873094.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30597-604 [10899173.001]
  • [Cites] Growth Horm IGF Res. 2002 Aug;12(4):193-7 [12175651.001]
  • [Cites] Pancreas. 1997 Nov;15(4):367-73 [9361090.001]
  • (PMID = 18263593.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113766-01A2; United States / NCI NIH HHS / CA / K08 CA113766; United States / NCI NIH HHS / CA / CA113766-02; United States / NCI NIH HHS / CA / K08 CA113766-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.2 / Focal Adhesion Kinase 1
  • [Other-IDs] NLM/ PMC2902396
  •  go-up   go-down


55. Izumi S, Nakamura S, Mano S, Suzuka I: Resection of four synchronous invasive ductal carcinomas in the pancreas head and body associated with pancreatic intraepithelial neoplasia: report of a case. Surg Today; 2009;39(12):1091-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of four synchronous invasive ductal carcinomas in the pancreas head and body associated with pancreatic intraepithelial neoplasia: report of a case.
  • This report describes a very rare case of four synchronous invasive ductal carcinomas (IDCs) in the pancreas head and body with possible multicentricity.
  • Abdominal dynamic computed tomography showed four low-density masses (25 mm, 20 mm, 10 mm, and 10 mm in diameter) in the pancreas head and body.
  • Histologically, the discontinuity between the four tumors was confirmed; one tumor (20 mm) was moderately differentiated tubular adenocarcinoma, and the others (25 mm, 10 mm, and 10 mm) were papillary adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasm Invasiveness / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2006 Jan;139(1):104-8 [16364723.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(3):316-20 [10982633.001]
  • [Cites] Pancreas. 1987;2(2):170-5 [2819857.001]
  • [Cites] Am J Surg. 1977 May;133(5):590-2 [871189.001]
  • [Cites] Pancreas. 1998 Jul;17 (1):102-5 [9667529.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):693-702 [16362976.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(2):125-36 [14505145.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] Surg Today. 2008;38(6):563-6 [18516541.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(5):549-53 [18836812.001]
  • [Cites] Pancreas. 2005 Aug;31(2):198-9 [16025010.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):138-43 [8439212.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • (PMID = 19997809.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Bersch VP, Osvaldt AB, Edelweiss MI, Schumacher Rde C, Wendt LR, Abreu LP, Blom CB, Abreu GP, Costa L, Piccinini P, Rohde L: Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice. Pancreas; 2009 Jan;38(1):65-70
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of nicotine and cigarette smoke on an experimental model of intraepithelial lesions and pancreatic adenocarcinoma induced by 7,12-dimethylbenzanthracene in mice.
  • Pancreatic adenocarcinoma has a higher frequency in the DMBA-n group (14 [51.9%]) than in the DMBA-e (4 [16.7%]) and DMBA-s (4, 13.3%) groups.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinogens / toxicity. Carcinoma in Situ / etiology. Nicotine / toxicity. Pancreatic Neoplasms / etiology. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824948.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


57. Griffin CA, Morsberger L, Hawkins AL, Haddadin M, Patel A, Ried T, Schrock E, Perlman EJ, Jaffee E: Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations. Cytogenet Genome Res; 2007;118(2-4):148-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic characterization of pancreas cancer cell lines reveals high complexity chromosomal alterations.
  • Karyotype analysis can provide clues to significant genes involved in the genesis and growth of pancreas cancer.
  • The genome of pancreas cancer is complex, and G-band analysis cannot resolve many of the karyotypic abnormalities seen.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosome Banding. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Metaphase. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 18000365.001).
  • [ISSN] 1424-859X
  • [Journal-full-title] Cytogenetic and genome research
  • [ISO-abbreviation] Cytogenet. Genome Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 38
  •  go-up   go-down


58. Chiang KC, Hsu JT, Chen HY, Jwo SC, Hwang TL, Jan YY, Yeh CN: Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report. World J Gastroenterol; 2009 Feb 7;15(5):628-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal intraductal papillary mucinous neoplasm of the pancreas--a case report.
  • Cystic neoplasms of the pancreas are relatively rare, comprising 10 percent of pancreatic cysts and only 1 percent of pancreatic cancers.
  • Cystic neoplasms include mucinous cystic neoplasms, serous cystadenomas, papillary cystic tumors, cystic islet cell tumors and intraductal papillary mucinous neoplasms of the pancreas (IPMNs).
  • Here we present a 72-year-old male diagnosed with IPMN (carcinoma in situ) in the pancreatic head and a branch duct type IPMN (duct atypia) in the pancreatic body and tail.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / radiography. Carcinoma in Situ / ultrasonography. Endoscopy. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Outcome. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Pancreas. 2001 May;22(4):370-7 [11345137.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):188-91 [11574095.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):34-43 [11781278.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):701-14 [11979253.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Radiology. 1987 Oct;165(1):51-5 [3306789.001]
  • [Cites] Hum Pathol. 1989 Aug;20(8):806-7 [2744753.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Pancreas. 1991 Jan;6(1):15-22 [1994377.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):133-8 [1851707.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):199-201 [1851710.001]
  • [Cites] Pancreas. 1992;7(1):114-7 [1557339.001]
  • [Cites] Am J Gastroenterol. 1992 May;87(5):634-8 [1317671.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jan;5(1):237-58 [7728346.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6 [9230804.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):556-9 [9831858.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Eur J Surg. 1999 Mar;165(3):223-9 [10231655.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1965 Jun;161:845-63 [14295937.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):460-8 [16616351.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):93-8 [10597405.001]
  • (PMID = 19195068.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653357
  •  go-up   go-down


59. Watanabe H, Okada G, Ohtsubo K, Yamaguchi Y, Mouri H, Motoo Y, Wakabayashi T, Sawabu N: Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas; 2005 May;30(4):349-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.
  • Mesothelin mRNA expression was confirmed with in situ hybridization in all 4 resected primary PCa tumors and with RT-PCR in 18 of 20 PCa cell lines, whereas mesothelin protein expression was confirmed with immunohistochemistry in all 60 resected primary PCa tissues by Argani et al.
  • We evaluated mesothelin mRNA expression in pure pancreatic juice (PPJ) obtained from patients with PCa, chronic pancreatitis (CP), and intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Membrane Glycoproteins / genetics. Pancreatic Neoplasms / diagnosis. Pancreatitis, Chronic / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841046.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


60. Shin SH, Han DJ, Park KT, Kim YH, Park JB, Kim SC: Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg; 2010 Apr;34(4):776-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND: The objective of the present study was to identify reliable preoperative factors predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm (IPMN) of the pancreas and the effectiveness of a diagnostic scoring system based on these factors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Carcinoma in Situ / pathology. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Predictive Value of Tests. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):967-71 [11490850.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1166-9 [12045867.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2000 Jun;179(6):482-4 [11004335.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Pancreas. 2009 Jan;38(1):8-16 [18665010.001]
  • [Cites] J Gastrointest Surg. 2004 Sep-Oct;8(6):713-9 [15358333.001]
  • [Cites] Pancreas. 2006 Apr;32(3):281-7 [16628084.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):183-8 [18392712.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Arch Surg. 2003 Jun;138(6):610-7; discussion 617-8 [12799331.001]
  • [Cites] Ann Surg. 1998 Nov;228(5):685-91 [9833807.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] J Surg Oncol. 2009 Jul 1;100(1):13-8 [19384908.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Pancreas. 2008 Jan;36(1):50-5 [18192881.001]
  • (PMID = 20127242.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Dumitrescu D, Popescu CF, Săftoiu A: Intraductal papillary mucinous tumors of the pancreas. Rom J Morphol Embryol; 2010;51(3):447-53
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas.
  • Based on the degree of cytoarchitectural atypia on microscopic examination, IPMTs are classified as benign, borderline, carcinoma in situ and invasive tumors.
  • Imaging examinations are very important to establish the diagnosis.
  • Transabdominal ultrasound, endoscopic ultrasound, computed tomography, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangio-pancreatography have been used for the diagnosis of IPMTs.
  • The correct diagnosis, achieved until recently only with endoscopic retrograde cholangiopancreatography, can be currently obtained with non-invasive imaging modalities, particularly computed tomography and magnetic resonance imaging.
  • Confirmation of the diagnosis requires, however, endoscopic-ultrasound fine-needle aspiration biopsy, followed by cytological or microhistological exams.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Humans. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809019.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  •  go-up   go-down


62. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, Nakamori S, Monden M, Mori M, Doki Y, Bepler G: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene; 2009 Aug 13;28(32):2903-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
  • We determined in situ RRM1 and excision repair cross complementation group 1 (ERCC1) protein levels in 68 pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / biosynthesis. Endonucleases / biosynthesis. Pancreatic Neoplasms / pathology. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorescent Antibody Technique / methods. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Pancreas / drug effects. Pancreas / metabolism. Pancreas / surgery. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4298-304 [11731512.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4553-61 [14555530.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1318-25 [14977831.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1878-85 [15143080.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3761-6 [15172981.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5776-87 [15199134.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6950-6 [15466186.001]
  • [Cites] Biochem Cell Biol. 1990 Dec;68(12):1364-71 [2085432.001]
  • [Cites] J Biol Chem. 1992 Apr 5;267(10):7066-71 [1551913.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2118-23 [8104092.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5 [8554125.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):347-53 [8805925.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):3-15 [8893876.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13181-6 [9371820.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):309-16 [9440758.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):78-85 [10444166.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3968-71 [10463593.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4204-7 [10485455.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2215-21 [15788669.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):907-21 [15825074.001]
  • [Cites] Oncology. 2005;68(2-3):171-8 [16006754.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9510-6 [16230416.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3928-35 [16585222.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6497-502 [16818620.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4731-7 [16966686.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1818-25 [16980606.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1355-63 [17131328.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):800-8 [17314339.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2212-7 [17538165.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2741-6 [17602079.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):39-44 [18077217.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):615-21 [17520253.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179 [18309957.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4225-31 [18594004.001]
  • [Cites] JOP. 2008;9(4):391-7 [18648128.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2A):645-52 [10810335.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2527-36 [11489836.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2135-42 [12687015.001]
  • (PMID = 19543324.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129343; United States / NCI NIH HHS / CA / R01 CA140314; United States / NCI NIH HHS / CA / R01-CA129343
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA-Binding Proteins; 0 / RRM1 protein, human; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  • [Other-IDs] NLM/ NIHMS521358; NLM/ PMC3913371
  •  go-up   go-down


63. Fan F, Lai EC, Xie F, Yang JM, Xu F, Kan T, Shen RX, Yang XY, Lau Wan Y, Wu MC: Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy. Hepatogastroenterology; 2010 May-Jun;57(99-100):635-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas--predictors of malignancy.
  • RESULTS: Thirteen patients (32.5%) had adenomas, 4 (10%) borderline IPMN, 18 (45%) carcinoma in situ, and 5 (12.5%) invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698241.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


64. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA: Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res; 2005 May 15;11(10):3766-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm.
  • PURPOSE: Patients with metastatic adenocarcinoma of unknown origin are a common clinical problem.
  • In the first (training) round, we studied 352 primary adenocarcinomas, from seven main sites (breast, colon, lung, ovary, pancreas, prostate and stomach) and their differential diagnoses.
  • CONCLUSIONS: This classification scheme should enable better prediction on biopsy material of the primary site in patients with metastatic adenocarcinoma of unknown origin, leading to improved management and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Predictive Value of Tests. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897574.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Chetty R, Serra S, Salahshor S, Alsaad K, Shih W, Blaszyk H, Woodgett JR, Tsao MS: Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis. Hum Pathol; 2006 Feb;37(2):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Wnt-signaling pathway proteins in intraductal papillary mucinous neoplasms of the pancreas: a tissue microarray analysis.
  • It is less frequently involved in conventional ductal pancreatic adenocarcinoma.
  • This pathway has not been explored in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas previously and formed the basis of this study.
  • The IPMNs were classified as 8 adenomas, 3 borderline, and 7 cases with carcinoma in situ and/or invasive carcinoma, occurring in 13 females, and the overall age range was 45 to 73 years.
  • The cases with nuclear beta-catenin localization included 1 adenoma, 2 borderline IPMN, and 4 carcinomas in situ and/or invasive carcinomas.
  • There was progressive decrease in membrane staining of E-cadherin in 2 of 3 borderline lesions, 1 of 2 carcinomas in situ, and 4 of 5 invasive carcinomas.
  • [MeSH-major] Adenoma / physiopathology. Carcinoma in Situ / physiopathology. Carcinoma, Pancreatic Ductal / physiopathology. Pancreatic Neoplasms / physiopathology. Wnt Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426922.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Wnt Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


66. Tanno S, Nakano Y, Nishikawa T, Nakamura K, Sasajima J, Minoguchi M, Mizukami Y, Yanagawa N, Fujii T, Obara T, Okumura T, Kohgo Y: Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut; 2008 Mar;57(3):339-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results.
  • BACKGROUND AND AIMS: Although branch duct intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas without mural nodules are frequently observed in asymptomatic subjects, the natural history of these lesions has never been studied.
  • Histological analysis revealed three cases classified as adenoma and one as carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):598-9 [18797440.001]
  • [CommentIn] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • (PMID = 17660227.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Wada K, Kozarek RA, Traverso LW: Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg; 2005 May;189(5):632-6; discussion 637

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas.
  • Survival was compared between 3 groups: noninvasive IPMN (n = 75), invasive IPMN (n = 25), and invasive ductal adenocarcinoma (n = 24), the latter matched by tumor-node-metastasis (TNM) stage to the IPMN invasive group.
  • Survival curves were not different (P = .11) between the cases matched by stage for those with invasive IPMN cases versus cases with ductal adenocarcinoma.
  • CONCLUSION: Patients with the invasive form of IPMN will have a similarly poor survival as those with ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / surgery
  • [MeSH-minor] Aged. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862510.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S: 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg; 2007 Dec;246(6):932-7; discussion 937-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
  • OBJECTIVE: To assess the reliability of 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) in distinguishing benign from malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas and its contribution to surgical decision making.
  • 18-FDG PET as imaging procedure based on the increased glucose uptake by tumor cells has been suggested for diagnosis and staging of pancreatic cancer.
  • The validation of the diagnosis was made by a surgical procedure (n = 44), a percutaneous biopsy (n = 2), main duct cytology (n = 1), or follow-up (n = 17).
  • An adenoma was diagnosed in 13 patients, a borderline tumor in 8, a carcinoma in situ in 5, and an invasive cancer in 21; in 17 patients a tumor sampling was not performed and therefore the histology remained undetermined.
  • Positive criteria of increased uptake on 18-FDG PET was absent in 13 of 13 adenomas and 7 of 8 borderline IPMNs, but was present in 4 of 5 carcinoma in situ (80%) and in 20 of 21 invasive cancers (95%).
  • Conventional imaging technique was strongly suggestive of malignancy in 2 of 5 carcinomas in situ and in 13 of 21 invasive carcinomas (62%).
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043094.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


69. Ott C, Heinmöller E, Gaumann A, Schölmerich J, Klebl F: [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma]. Med Klin (Munich); 2007 Feb 15;102(2):127-35
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma].
  • Pancreatic intraepithelial neoplasias (PanIN) have been recognized as precursor lesions of ductal adenocarcinoma, and are classified into different grades from PanIN-1A, -1B, -2, to -3.
  • Becoming invasive, some of these tumors appear as ductal adenocarcinoma, others as colloid carcinoma with a much better prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous. Adenocarcinoma, Papillary. Carcinoma in Situ. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor. Disease Progression. Humans. Middle Aged. Mutation. Pancreas / pathology. Pancreatic Ducts / pathology. Precancerous Conditions / pathology. Prognosis. Retrospective Studies. Risk Factors. Terminology as Topic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323019.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


70. Crippa S, Salvia R, Warshaw AL, Domínguez I, Bassi C, Falconi M, Thayer SP, Zamboni G, Lauwers GY, Mino-Kenudson M, Capelli P, Pederzoli P, Castillo CF: Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg; 2008 Apr;247(4):571-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.
  • OBJECTIVE: Mucinous cystic neoplasms (MCNs) of the pancreas have often been confused with intraductal papillary mucinous neoplasms.
  • RESULTS: MCNs were seen mostly in women (95%) and in the distal pancreas (97%); 25% were incidentally discovered.
  • One hundred eighteen patients (72%) had adenoma, 17 (10.5%) borderline tumors, 9 (5.5%) in situ carcinoma, and 19 (12%) invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1320-7 [10555000.001]
  • [Cites] Ann Surg. 2000 Feb;231(2):205-12 [10674612.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):139-52 [11812936.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10(3):515-25 [12684617.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):198-205 [12892797.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1221-8 [12960806.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Surg Gynecol Obstet. 1987 Dec;165(6):475-8 [2446398.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Ann Surg. 1990 Oct;212(4):432-43; discussion 444-5 [2171441.001]
  • [Cites] Pancreas. 1991 Jan;6(1):15-22 [1994377.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1078-91 [7943529.001]
  • [Cites] Virchows Arch. 1994;424(1):53-7 [7981904.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31 [15551256.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Am Coll Surg. 2005 May;200(5):727-33 [15848365.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Pancreas. 2005 Jul;31(1):79-83 [15968252.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):927-31 [16112012.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Pathol Int. 2006 Feb;56(2):71-7 [16445818.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] Arch Surg. 2006 Apr;141(4):361-5; discussion 366 [16618893.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Dig Surg. 2006;23(3):186-91 [16837797.001]
  • [Cites] World J Surg. 2006 Dec;30(12):2236-45 [17103100.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):77-82 [17592294.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] Br J Surg. 2008 Jan;95(1):85-91 [18041022.001]
  • [CommentIn] Ann Surg. 2008 Apr;247(4):580-2 [18362620.001]
  • (PMID = 18362619.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK071329
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS517373; NLM/ PMC3806104
  •  go-up   go-down


71. Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, Ouellette MM: Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology; 2007 Oct;51(4):539-46
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
  • The aim of this study was to examine TUBB3 expression in pancreatic cancer cell lines, invasive pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).
  • TUBB3 was undetectable in non-neoplastic ducts of the pancreas.
  • [MeSH-major] Adenocarcinoma / metabolism. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma in Situ / metabolism. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Pancreatic Neoplasms / metabolism. Tubulin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17714470.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA111294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / TUBB3 protein, human; 0 / Tubulin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


72. Uehara H, Nakaizumi A, Iishi H, Takenaka A, Eguchi H, Ohigashi H, Ishikawa O: In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas; 2008 Apr;36(3):236-40
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases.
  • In the present study using an in situ TRAP assay, we investigated the specificity of telomerase activity in pancreatic juice for pancreatic cancer.
  • METHODS: Pancreatic juice were obtained endoscopically at endoscopic retrograde cholangiopancreatography from 10 patients with pancreatic cancer, 4 with intraductal papillary neoplasm, and 3 with normal pancreas.
  • In situ telomerase activity in pancreatic juice samples was examined by in situ TRAP assay and was compared with the results of cytological examination.
  • RESULTS: Of 10 samples from pancreatic cancer, high telomerase activity in situ was detected in 9 and cancer cells in 7.
  • Of 4 samples from intraductal papillary neoplasm, low telomerase activity in situ and mild atypical cells were detected in 2.
  • Telomerase activity in situ was detected in none of 3 samples from normal pancreas.
  • CONCLUSIONS: Detection of in situ telomerase activity in pancreatic juice might help discriminate pancreatic cancer from other pancreatic diseases.
  • [MeSH-major] Pancreatic Diseases / diagnosis. Pancreatic Diseases / enzymology. Pancreatic Juice / enzymology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / enzymology. Aged. Base Sequence. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / enzymology. Case-Control Studies. DNA Primers / genetics. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362835.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


73. Rautou PE, Lévy P, Vullierme MP, O'Toole D, Couvelard A, Cazals-Hatem D, Palazzo L, Aubert A, Sauvanet A, Hammel P, Hentic O, Rebours V, Pelletier AL, Maire F, Ruszniewski P: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol; 2008 Jul;6(7):807-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study.
  • BACKGROUND & AIMS: Because there is a low risk of malignancy for intraductal papillary and mucinous neoplasms of the pancreas (IPMNs) confined to branch ducts (BD), patient follow-up evaluation without surgery is possible.
  • Surgery, performed in 8 of 12 patients, found 4 IPMN-adenomas, 1 borderline-IPMN, and 4 IPMN carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2008 Jul;6(7):724-5 [18602034.001]
  • (PMID = 18304885.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG: Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer; 2009 Aug 15;125(4):942-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma carries an ominous prognosis and has little effective treatment.
  • Several studies have demonstrated that the potently antiapoptotic phosphatidyl inositol 3'-kinase (PI3K)-protein kinase B/AKT pathway is active in pancreas cancer.
  • We screened several cell permeable peptides from the N-terminal domain of CTMP (termed TAT-CTMP1-4) in vitro and found one that caused significant apoptosis in pancreatic adenocarcinoma cell lines.
  • A screening of various cell and tissue types revealed that the proapoptotic activity was highest in pancreatic adenocarcinoma.
  • We further showed that TAT-CTMP4 could augment either gemcitabine chemotherapy or radiation therapy, standard therapies for pancreas cancer.
  • Pancreatic adenocarcinoma xenografts treated with a single dose of TAT-CTMP4 demonstrated a marked increase in caspase-3 positive tumor cells when compared with untreated controls.
  • Additionally, pancreatic adenocarcinoma allografts treated with intratumoral TAT-CTMP and systemic gemcitabine displayed a significantly smaller tumor burden while undergoing treatment than mice in control groups (p < 0.001).
  • These data indicate that inhibiting AKT with CTMP may be of therapeutic benefit in the treatment of pancreatic adenocarcinoma and, when combined with established therapies, may result in an increase in tumor cell death.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6105-11 [11507060.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3269-75 [11595724.001]
  • [Cites] Science. 2001 Oct 12;294(5541):374-80 [11598301.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Int J Oncol. 1998 Jan;12(1):141-52 [9454898.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):989-97 [12481421.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):346-54 [12538487.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Bioconjug Chem. 2003 Mar-Apr;14(2):368-76 [12643747.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):7-11 [14749121.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2950-66 [15077156.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Anticancer Res. 1995 Jul-Aug;15(4):1135-9 [7653991.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1997 Jan;27(1):47-57 [9002166.001]
  • [Cites] Science. 1999 Apr 9;284(5412):339-43 [10195903.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S69-77 [15316751.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):5-10 [15651171.001]
  • [Cites] Gen Physiol Biophys. 2004 Jun;23(2):209-29 [15696860.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):227-38 [15766661.001]
  • [Cites] Z Gastroenterol. 2005 Oct;43(10):1133-9 [16220453.001]
  • [Cites] Infect Immun. 2005 Dec;73(12):8275-81 [16299324.001]
  • [Cites] J Androl. 2006 Mar-Apr;27(2):285-93 [16474026.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5471-7 [16622015.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 6;355(2):501-7 [17307150.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):566-72 [17414605.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1763-71 [17206479.001]
  • [Cites] Pancreas. 2007 Oct;35(3):e16-26 [17895832.001]
  • [Cites] Oncogene. 2007 Oct 25;26(49):7038-48 [17486061.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Nov;293(5):C1576-85 [17615157.001]
  • [Cites] Gene Ther. 2007 Dec;14(24):1721-30 [17960162.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):431-7 [11485901.001]
  • (PMID = 19405118.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM044118; United States / NIGMS NIH HHS / GM / GM44118; United States / NCI NIH HHS / CA / T32 CA009621; United States / NCI NIH HHS / CA / T32 CA09621; United States / NIGMS NIH HHS / GM / GM044118-08; United States / NIGMS NIH HHS / GM / GM055194-03; United States / NIGMS NIH HHS / GM / R01 GM044118-08; United States / NCI NIH HHS / CA / T32 CA009621-11; United States / NIGMS NIH HHS / GM / R01 GM055194-03; United States / NIGMS NIH HHS / GM / R01 GM055194; United States / NIGMS NIH HHS / GM / GM55194; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NIGMS NIH HHS / GM / R37 GM044118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / tat Gene Products, Human Immunodeficiency Virus; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.2.- / THEM4 protein, human; EC 3.1.2.- / Thiolester Hydrolases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS109118; NLM/ PMC3645501
  •  go-up   go-down


75. Salvia R, Partelli S, Crippa S, Landoni L, Capelli P, Manfredi R, Bassi C, Pederzoli P: Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg; 2009 Nov;198(5):709-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts.
  • PATIENTS AND METHODS: Our database of patients affected by IPMN was queried to identify patients with a clinicoradiologic or a pathologic diagnosis of multifocal BD-IPMN between January 1990 and December 2006.
  • RESULTS: One hundred thirty-one patients (52 male and 79 female; median age 67 years) had a clinicoradiologic or a histopathologic diagnosis of multifocal BD-IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Female. Humans. Male. Middle Aged. Pancreatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887201.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


76. Brune K, Abe T, Canto M, O'Malley L, Klein AP, Maitra A, Volkan Adsay N, Fishman EK, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH: Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol; 2006 Sep;30(9):1067-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.
  • Some individuals with a strong family history of pancreatic cancer develop multifocal, noninvasive epithelial precursor lesions of the pancreas.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1971 Jun;63(3):521-46 [5581235.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:9 [12556240.001]
  • [Cites] Br J Exp Pathol. 1981 Dec;62(6):547-58 [7326214.001]
  • [Cites] Am J Pathol. 1987 Mar;126(3):439-51 [3826300.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1511-4 [3587280.001]
  • [Cites] Radiology. 1989 Feb;170(2):411-5 [2536185.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 7;85(13):1020-1 [8515481.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1215-25 [8261515.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):555-64 [8119204.001]
  • [Cites] Am J Pathol. 1994 May;144(5):889-95 [8178941.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):875-84 [8608898.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):251-75 [8623061.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):7-8 [8782809.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Gastrointest Endosc. 1998 Jul;48(1):11-7 [9684658.001]
  • [Cites] Gastrointest Endosc. 1998 Jul;48(1):18-25 [9684659.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):379-83 [9697701.001]
  • [Cites] Vet Radiol Ultrasound. 1998 Nov-Dec;39(6):557-62 [9845197.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):728-41 [15765408.001]
  • [Cites] PLoS Med. 2004 Dec;1(3):e65 [15630470.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1149-57 [16088887.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch A Pathol Pathol Anat. 1970;349(1):69-79 [4907111.001]
  • [Cites] Am J Pathol. 1975 Aug;80(2):203-26 [169698.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Radiol Clin North Am. 2000 Jul;38(4):625-51 [10943268.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1447-53 [11113065.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):738-44 [11297271.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):266-73 [11561603.001]
  • [Cites] Endoscopy. 2001 Oct;33(10):824-31 [11571676.001]
  • [Cites] Genet Epidemiol. 2002 Aug;23(2):133-49 [12214307.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):571-81 [12496492.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9361-9 [12522141.001]
  • [Cites] Dig Surg. 2003;20(6):520-6 [14534374.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):459-77 [14755677.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):456-62 [15113850.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [CommentIn] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • (PMID = 16931950.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-140011; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / CA062924-120011; United States / NCI NIH HHS / CA / P50 CA062924-130011; United States / NCI NIH HHS / CA / P50 CA062924-120011; United States / NCI NIH HHS / CA / R01 CA97075; United States / NCI NIH HHS / CA / R01 CA097075; United States / NCI NIH HHS / CA / CA062924-130011; United States / NCI NIH HHS / CA / CA062924-140011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS105552; NLM/ PMC2746409
  •  go-up   go-down


77. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA.
  • BACKGROUND: Studies indicate enhanced diagnostic accuracy for digital image analysis (DIA) and fluorescence in situ hybridization (FISH) versus routine cytology examination (RC) when biliary strictures are evaluated.
  • The final diagnosis was based on strict cytopathologic and imaging criteria and 12-month follow-up.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle. Endosonography. Esophageal Neoplasms / pathology. Image Processing, Computer-Assisted. In Situ Hybridization, Fluorescence. Lymphatic Metastasis / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagus / pathology. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Pilot Projects. Sensitivity and Specificity. Stomach / pathology


78. Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE: Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg; 2005 Mar;29(3):297-305
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
  • Global gene expression profiling holds promise for improved diagnosis and treatment.
  • We have compiled a list of overexpressed genes in pancreatic cancer for which overexpression was confirmed by reverse transcriptase polymerase chain reaction, immunohistochemistry, and/or in situ hybridization following initial identification by global gene expression profiling.
  • The S100 gene family, mesothelin, prostate stem cell antigen, and 14-3-3 sigma, may have important clinical implications in pancreatic cancer diagnosis and treatment.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression / physiology. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1999 Apr;90(4):425-31 [10363581.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):595-600 [12479219.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Feb;16(1):37-52 [12063828.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):441-7 [11950919.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7437-46 [11704875.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):33-7 [9915498.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Electrophoresis. 1999 Oct;20(14):2952-60 [10546833.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 9;281(4):936-44 [11237751.001]
  • [Cites] J Immunother. 2000 Jul-Aug;23(4):473-9 [10916757.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4158-66 [12874021.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):819-26 [11830538.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3221-8 [11848476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4256-61 [10759549.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):119-24 [8617452.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4587-94 [12085237.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1288-96 [10713670.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):45-50 [11786397.001]
  • [Cites] Eur J Immunol. 2002 Mar;32(3):826-36 [11870627.001]
  • [Cites] Cell Mol Life Sci. 2003 Jun;60(6):1180-99 [12861384.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45201-6 [11574543.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1239-49 [11943709.001]
  • [Cites] World J Surg. 2002 Jul;26(7):783-9 [11948367.001]
  • (PMID = 15696394.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA85822; United States / NCI NIH HHS / CA / R13 CA 1011889
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / S100 Proteins; 0 / mesothelin; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  • [Number-of-references] 39
  •  go-up   go-down


79. Takahashi H, Nakamori S, Nakahira S, Tsujie M, Takahshi Y, Marubashi S, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. Ann Surg Oncol; 2006 Jul;13(7):955-60
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • RESULTS: Of the 20 patients, 13 had benign IPMNs, including adenomas (n = 10) and borderlines (n = 3), and 7 had malignant IPMNs, including carcinomas in situ (n = 4) and minimally invasive IPMNs (n = 3).
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Pancreatectomy / methods. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788757.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Yang AD, Melstrom LG, Bentrem DJ, Ujiki MB, Wayne JD, Strouch M, Bell RH, Rao SM, Talamonti MS: Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery; 2007 Oct;142(4):529-34; discussion 534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
  • Nine patients had adenomas, 14 had borderline neoplasms, 10 had carcinoma in situ, and 9 had invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / statistics & numerical data. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950345.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Baiocchi GL, Portolani N, Missale G, Baronchelli C, Gheza F, Cantù M, Grazioli L, Giulini SM: Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications. World J Surg Oncol; 2010;8:25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications.
  • Total pancreatectomy was performed in 46% of the cases; in situ and invasive carcinoma were recognized in 15.4% and 38.4% of the cases, respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatectomy. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):181-93 [10952400.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):376-81 [11260102.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):701-7 [12397279.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] J Comput Assist Tomogr. 2004 Jan-Feb;28(1):117-22 [14716244.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Int J Pancreatol. 1995 Dec;18(3):197-206 [8708390.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1981-5 [9951851.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Endoscopy. 2006 Jun;38 Suppl 1:S40-7 [16802222.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):304-7 [17693271.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):932-7; discussion 937-9 [18043094.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):571-9 [18362619.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 20374620.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2858722
  •  go-up   go-down


82. Kalinina T, Güngör C, Thieltges S, Möller-Krull M, Penas EM, Wicklein D, Streichert T, Schumacher U, Kalinin V, Simon R, Otto B, Dierlamm J, Schwarzenbach H, Effenberger KE, Bockhorn M, Izbicki JR, Yekebas EF: Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer; 2010;10:295
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung.
  • Numerous genes were overexpressed, some of which have previously been implicated in pancreatic adenocarcinoma (GATA6, IGFBP3, IGFBP6), while others were detected for the first time (MEMO1, RIOK3).
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Culture Techniques. Cell Line, Tumor. Cell Proliferation. Cell Separation. Cell Shape. DNA-Binding Proteins / deficiency. DNA-Binding Proteins / genetics. Dose-Response Relationship, Drug. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Pore Forming Cytotoxic Proteins / deficiency. Pore Forming Cytotoxic Proteins / genetics. Time Factors. Tumor Burden. Xenograft Model Antitumor Assays


83. Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, Schmid RM, Siveke JT: Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A; 2010 Jul 27;107(30):13438-43
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Receptor, Notch2 / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Disease Progression. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mice. Mice, Knockout. Pancreas / metabolism. Pancreas / pathology. Proto-Oncogene Proteins c-myc / genetics. Proto-Oncogene Proteins c-myc / metabolism. Proto-Oncogene Proteins p21(ras) / genetics. Proto-Oncogene Proteins p21(ras) / metabolism. Receptor, Notch1 / genetics. Receptor, Notch1 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction


84. Chetty R, Serra S: Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm. Histopathology; 2009 Sep;55(3):270-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular adenoma (pyloric gland-type) of the pancreas: a reappraisal and possible relationship with gastric-type intraductal papillary mucinous neoplasm.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2010 Jun;56(7):968-9; author reply 969 [20636797.001]
  • (PMID = 19723141.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM, Settmacher U, Hommann M, Richter KK, Daffner W, Täubig H, Manger T, Claussen U, von Eggeling F: Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem; 2007 Apr;53(4):629-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker.
  • We identified proteins by use of 2-dimensional gel electrophoresis, peptide fingerprint mapping, and immunodepletion and used immunohistochemistry for in situ localization of the proteins found.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Heat-Shock Proteins / analysis. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. Proteome / analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303689.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


86. Goh BK, Chung YF, Ng DC, Selvarajan S, Soo KC: Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP; 2007;8(3):350-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas.
  • A total pancreatectomy was performed and the final histology demonstrated a main-duct type intraductal papillary mucinous neoplasm with a focus of high-grade dysplasia compatible with carcinoma-in-situ.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Fluorodeoxyglucose F18. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495366.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


87. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, Fujita Y, Uchiyama K, Yamaue H: Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg; 2009 Apr;144(4):345-9; discussion 349-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
  • PATIENTS: Fifty-four patients with IPMN who underwent surgery; histologic examination showed benign adenomas in 29, carcinoma in situ in 14, and invasive carcinoma in 11 patients.
  • CONCLUSION: Measurement of the CEA level in pancreatic juice should be considered in the diagnosis of IPMC.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380648.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Wente MN, Schmied BM, Schmidt J, Büchler MW: [Differentiated therapy for intraductal papillary mucinous neoplasms]. Chirurg; 2009 Jan;80(1):7-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are of increasing interest in the field of pancreatic surgery ever since their first description as an individual pancreatic tumor entity in 1982.
  • Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Prognosis. Radiography, Dual-Energy Scanned Projection. Survival Rate. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):322-33 [18813200.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] Gut. 2008 Nov;57(11):1490-1 [18941002.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):414-6 [17968632.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] J Clin Pathol. 2008 Dec;61(12):1303-13 [18703569.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19082569.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


89. Sanada Y, Yoshida K, Ohara M, Tsutani Y: Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res; 2007;13(2):105-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of pancreatic intraepithelial neoplasia (PanIN) were counted, and histologic subtypes of invasive ductal carcinoma of the pancreas (IDC) were determined.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma in Situ / enzymology. Carcinoma, Hepatocellular / enzymology. Gallbladder Neoplasms / enzymology. Liver Neoplasms / enzymology. Orotate Phosphoribosyltransferase / metabolism. Pancreatic Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Gallbladder / enzymology. Gallbladder / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Liver / enzymology. Liver / pathology. Male. Middle Aged. Pancreas / enzymology. Pancreas / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2006;6(5):429-39 [16847380.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):987-92 [16142362.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Nov;32(12):1929-34 [16282729.001]
  • [Cites] Pancreas. 2004 Apr;28(3):257-62 [15084967.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):607-15 [16880781.001]
  • [Cites] Cancer. 2005 Jan 1;103(1):111-8 [15558814.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):245-9 [16012756.001]
  • [Cites] Eur J Cancer. 2003 May;39(7):975-80 [12706367.001]
  • [Cites] Pancreas. 2006 Mar;32(2):164-70 [16552336.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):45-50 [16788943.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):723-31 [14770427.001]
  • [Cites] Pancreas. 2005 Apr;30(3):223-6 [15782098.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):230-6 [1309358.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1223-30 [16211289.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):492-8 [16734727.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):39-62 [15757804.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):621-8 [15105650.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):345-51 [15993511.001]
  • (PMID = 17607371.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


90. Amillet JM, Ferbus D, Real FX, Antony C, Muleris M, Gress TM, Goubin G: Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Hum Pathol; 2006 Mar;37(3):256-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Absent or very faint expression was observed in normal pancreas cell extracts.
  • Immunohistochemical analysis of Rab20 in tissues showed low or absent expression in normal pancreas and stronger expression in 15 of 18 exocrine pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Regulation, Neoplastic. Pancreas, Exocrine / metabolism. Pancreatic Neoplasms / genetics. rab GTP-Binding Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Biomarkers, Tumor / metabolism. Blotting, Western. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / ultrastructure. HeLa Cells. Humans. Immunoenzyme Techniques. Molecular Sequence Data. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Sequence Homology, Amino Acid

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613320.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.6.1- / Rab20 protein, human; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


91. Egawa S, Sunamura M, Abe H, Motoi F, Fukuyama S, Matsuno S: [Clinicopathological aspects of pancreatic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):605-11
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the nationwide database of the Japan Pancreas Society (JPS), the clinicopathological features of 23,284 cases (1981-2000) and 2,298 cases (2001-2002) with pancreatic neoplasms were compared.
  • The numbers of serous cystadenocarcinomas and carcinomas in situ were decreased.
  • The proportion of less differentiated adenocarcinoma was increased in the more advanced stages of the disease.
  • In Stage IVa, the survival of the patients with papillary adenocarcinoma was not statistically different from that of patients with well or moderate tubular adenocarcinoma, though the difference was significant in earlier stages.
  • The survival of the patients with poorly differentiated adenocarcinoma, adenosquamous carcinoma and undifferentiated carcinoma was miserable.
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / mortality. Cystadenocarcinoma, Mucinous / pathology. Humans. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918558.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Abe K, Suda K, Arakawa A, Yamasaki S, Sonoue H, Mitani K, Nobukawa B: Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. Pancreas; 2007 Jan;34(1):85-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Either the loss of p16INK4A expression or the overexpression of p53 was much more frequently observed among PanIN-3 than among carcinoma in situ in IPMN (P = 0.046 and 0.008, respectively).
  • [MeSH-major] Carcinoma in Situ / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Pancreatic Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198188.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


93. Liang ZY, Wang WZ, Gao J, Wu SF, Zeng X, Liu TH: [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Feb;36(2):102-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expressions of TOP2A and HER2/neu proteins were detected by using immunohistochemistry, while gene amplifications of TOP2A and HER2/neu were assessed by using multi-color fluorescence in situ hybridization (FISH).
  • All the samples were of paraffin embedded and 10% formalin fixed tissue, including 26 cases of pancreatic ductal adenocarcinomas with adjacent non-neoplastic pancreatic tissues, 10 cases of chronic panreatitis, and 10 cases of normal pancreas.
  • By FISH, 9/10 TOP2A amplified adenocarcinomas showed TOP2A and HER2/neu gene coamplification, while one case with HER2/neu gene amplification adenocarcinoma showed no TOP2A amplification.
  • No expression of TOP2A, HER2/neu proteins and no amplification of TOP2A and HER2/neu gene were detected in adjacent non-neoplastic pancreatic tissues, chronic pancreatitis tissues and normal pancreas.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / metabolism. Carcinoma, Pancreatic Ductal / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Genes, erbB-2. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493384.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


94. Kipp BR, Fritcher EG, Clayton AC, Gores GJ, Roberts LR, Zhang J, Levy MJ, Halling KC: Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography. J Mol Diagn; 2010 Nov;12(6):780-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatobiliary tract strictures result either from malignancies of the biliary tract and pancreas or from nonmalignant etiopathogenesis.
  • The goal of this study was to determine whether KRAS mutations could be identified in residual pancreatobiliary stricture brushings and to compare the performance characteristics of KRAS mutation analysis to cytology and fluorescence in situ hybridization (FISH) for the detection of carcinoma.
  • Residual brushing cytology cell pellets were retrieved from 132 patients with subsequent clinicopathologic follow-up of cholangiocarcinoma (n = 41), pancreatic adenocarcinoma (n = 35), gallbladder cancer (n = 2), and nonmalignant strictures (n = 54).
  • KRAS mutations and polysomic (ie, positive) FISH results were identified in 24 (69%) and 22 (63%) pancreatic adenocarcinoma specimens, respectively, with a combined sensitivity of 86% (30/35).
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Cholangiopancreatography, Endoscopic Retrograde. Cytodiagnosis / methods. DNA Mutational Analysis / methods. In Situ Hybridization, Fluorescence / methods. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Jun 25;93(3):229-35 [11391612.001]
  • [Cites] Gut. 2001 Mar;48(3):403-8 [11171833.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):214-9 [15017605.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1675-81 [15330900.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):629-35 [10100716.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):412-20 [15467712.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1315-20 [16311354.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1064-72 [17030177.001]
  • [Cites] Diagn Cytopathol. 2007 Apr;35(4):218-24 [17351944.001]
  • [Cites] Am J Clin Pathol. 2007 Aug;128(2):272-9 [17638662.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] J Clin Gastroenterol. 2007 Nov-Dec;41(10):906-10 [18090159.001]
  • [Cites] Liver Int. 2008 Jan;28(1):12-27 [18031477.001]
  • [Cites] World J Gastroenterol. 2008 Feb 21;14(7):1097-101 [18286693.001]
  • [Cites] Hepatology. 2008 Jul;48(1):308-21 [18536057.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):353-360 [18075308.001]
  • [Cites] Oncol Res. 2008;17(4):151-7 [18773859.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Nov;6(11):1270-8 [18995218.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2180-6 [19232347.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Gastroenterology. 2009 Sep;137(3):1072-82, 1082.e1-6 [19501586.001]
  • [Cites] Arch Pathol Lab Med. 2009 Oct;133(10):1600-6 [19792050.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):543-52 [19815694.001]
  • [Cites] J Mol Diagn. 2009 Nov;11(6):583-9 [19815696.001]
  • [Cites] Pancreas. 2009 Nov;38(8):890-5 [19752775.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Diagn Cytopathol. 2002 May;26(5):273-7 [11992366.001]
  • (PMID = 20864634.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2963905
  •  go-up   go-down


95. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer; 2007 Mar 1;120(5):1046-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This has been accomplished with the application of real-time PCR profiling of over 200 microRNA precursors on specimens of human pancreatic adenocarcinoma, paired benign tissue, normal pancreas, chronic pancreatitis and nine pancreatic cancer cell lines.
  • Hierarchical clustering was able to distinguish tumor from normal pancreas, pancreatitis and cell lines.
  • The PAM algorithm correctly classified 28 of 28 tumors, 6 of 6 normal pancreas and 11 of 15 adjacent benign tissues.
  • Reverse transcription in situ PCR showed that three of the top differentially expressed miRNAs (miR-221, -376a and -301) were localized to tumor cells and not to stroma or normal acini or ducts.
  • Aberrant microRNA expression may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [Cites] Science. 2001 Sep 14;293(5537):2087-92 [11557892.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] Science. 2001 Oct 26;294(5543):858-62 [11679671.001]
  • [Cites] Science. 2001 Oct 26;294(5543):862-4 [11679672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2649-57 [12750293.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12754-9 [10535995.001]
  • [Cites] Dev Cell. 2003 Aug;5(2):351-8 [12919684.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Trends Biochem Sci. 2004 Sep;29(9):462-8 [15337119.001]
  • [Cites] Pancreas. 2004 Nov;29(4):254-63 [15502640.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):226-30 [15538371.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52361-5 [15504739.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12023-8 [16099838.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • (PMID = 17149698.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107435-02; United States / NCI NIH HHS / CA / R21 CA107435-02; United States / NCI NIH HHS / CA / P30 CA16058; United States / NCI NIH HHS / CA / CA107435; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / R21 CA107435
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS82895; NLM/ PMC2680248
  •  go-up   go-down






Advertisement